AstraZeneca, Amgen Score Phase 3 Win in Debilitating Swallowing Disease
AstraZeneca & Amgen’s Tezspire achieves significant Phase 3 CROSSING trial results in eosinophilic esophagitis (EoE) treatment.
Read original at benzingaStocks · News reference
Amgen To Terminate Research Collaboration And License Agreement With TScan Therapeutics; Termination Of Collaboration Agreement Effective November 10, 2026
On August 12, 2026, TScan Therapeutics, Inc. (the "Company") received notice from Amgen Inc. ("Amgen") of its election to terminate, in its entirety, the Research Collaboration and License Agreement,
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 18, 2026, 9:08 PM
- Checked
- Aug 18, 2026, 9:08 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
AstraZeneca, Amgen Report Phase III Results For TEZSPIRE In Eosinophilic Esophagitis; TEZSPIRE Meets Key Endpoints In Phase III CROSSING Trial
Statistically significant and clinically meaningful disease and symptom improvements compared to placebo maintained through week 52Efficacy in a third epithelial-driven inflammatory disease supports broad potential of
Read original at benzingaAmgen And AstraZeneca's TEZSPIRE Meets Both Co-Primary And All Key Secondary Endpoints In Phase 3 CROSSING Trial For Eosinophilic Esophagitis
Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52Efficacy in a Third Epithelial-Driven Inflammatory Disease Supports Broad Potential of
Read original at benzingaAI Poised to Reshape Blood Cancer Therapeutics as Investment Surges Past $2 Billion Across Leading Biotech and Pharma Players
Artificial intelligence is transforming blood cancer drug discovery and development, with over $2 billion in investment from major biotech and pharma companies. AI is reducing clinical trial timelines by up to 50%, improving patient selection, and enabling next-generation therapies like CAR-T and antibody-drug conjugates. North America leads with 40% of global market share, while Asia-Pacific emerges as a significant growth region.
Read original at globenewswire-inc12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers BioVie (NASDAQ:BIVI) stock increased by 15.7% to $1.55 during Wednesday's after-market session. The market value of their outstanding shares is at $7.2 million. The company's, Q4 earnings came out 4
Read original at benzinga8-K filing — TScan Therapeutics, Inc. (TCRX)
Filed: 2026-08-18 AccNo: 0001193125-26-355664 Size: 141 KB Item 1.02: Termination of a Material Definitive Agreement
Read original at edgar